Company research
FibroBiologics, Inc.
CIK 1958777Updated Oct 21, 2026
SecurityFBLG · NASDAQ · equity
Name history
FibroBiologics Inc. · through Feb 6, 2024
FBLG price & chart
Loading TradingView…
NASDAQ:FBLG on TradingView ↗About the company
We are a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Our most advanced product candidates are CYWC628, CYPS317, CYMS101 and CybroCellTM.
In the news
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers ↗
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial ↗
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them ↗
Recent filings
Show 5 more recent filings
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02, 9.01
Submission of Matters to a Vote of Security Holders · Regulation FD Disclosure
Items 5.07, 7.01, 9.01
SCHEDULE 13D - filed by Khoja Hamid regarding FibroBiologics, Inc.
D filing
Items 06b
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 8,744,000Source | 10,469,000Source | 7,929,000Source | 13,907,000Source | 8,912,000Source | 5,938,000Source | 11,426,000Source | 11,399,000Source | 9,619,000Source | 16,445,000Source | 11,821,000Source | 4,824,000Source |
| Property, Plant and Equipment, NetUSD | 908,000Source | 772,000Source | 710,000Source | 967,000Source | 799,000Source | 776,000Source | 814,000Source | 770,000Source | 842,000Source | 824,000Source | 797,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,867,000Source | 7,827,000Source | 3,515,000Source | 8,845,000Source | 5,973,000Source | 1,482,000Source | 8,667,000Source | 8,158,000Source | 4,894,000Source | 13,985,000Source | 9,163,000Source | 2,266,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 300,000Source |
| Assets, CurrentUSD | 5,240,000Source | 8,198,000Source | 5,850,000Source | 10,178,000Source | 6,509,000Source | 2,905,000Source | 9,327,000Source | 8,922,000Source | 6,349,000Source | 14,228,000Source | 9,215,000Source | 2,625,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,548,000Source | 1,499,000Source | 1,321,000Source | 2,714,000Source | 1,604,000Source | 2,209,000Source | 1,285,000Source | 1,707,000Source | 2,380,000Source | 1,393,000Source | 1,809,000Source | 2,199,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 8,619,000Source | 7,732,000Source | 3,293,000Source | 13,047,000Source | 11,299,000Source | 3,338,000Source | 9,076,000Source | 15,262,000Source | 3,463,000Source | 13,710,000Source | 10,568,000Source | 8,820,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | 0Source | — | — | 0Source | — | — | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 0Source | — | 1,000Source | 0Source | — | 1,000Source | — | — | 1,000Source | — | — | — |
| Additional Paid in CapitalUSD | 51,045,000Source | 35,156,000Source | 67,916,000Source | 46,002,000Source | 29,532,000Source | 61,763,000Source | 42,834,000Source | 28,954,000Source | 60,319,000Source | 38,253,000Source | 25,609,000Source | 2,414,000Source |
| Retained Earnings (Accumulated Deficit)USD | -50,920,000Source | -32,419,000Source | -63,281,000Source | -45,142,000Source | -31,919,000Source | -59,164,000Source | -40,484,000Source | -32,817,000Source | -54,164,000Source | -35,518,000Source | -24,357,000Source | -7,872,000Source |
| Stockholders' Equity Attributable to ParentUSD | 125,000Source | 2,737,000Source | 4,636,000Source | 860,000Source | -2,387,000Source | 2,600,000Source | 2,350,000Source | -3,863,000Source | 6,156,000Source | 2,735,000Source | 1,253,000Source | -3,996,000Source |
| Liabilities and EquityUSD | 8,744,000Source | 10,469,000Source | 7,929,000Source | 13,907,000Source | 8,912,000Source | 5,938,000Source | 11,426,000Source | 11,399,000Source | 9,619,000Source | 16,445,000Source | 11,821,000Source | 4,824,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,722,000Source | 6,677,000Source | 2,213,000Source | 10,964,000Source | 10,132,000Source | 1,829,000Source | 8,211,000Source | 13,985,000Source | 1,759,000Source | 12,726,000Source | 9,183,000Source | 7,073,000Source |
| Operating Lease, Liability, CurrentUSD | 643,000Source | 392,000Source | 258,000Source | 627,000Source | 382,000Source | 723,000Source | 412,000Source | 372,000Source | 706,000Source | 401,000Source | 362,000Source | 326,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,897,000Source | 1,055,000Source | 1,080,000Source | 2,083,000Source | 1,167,000Source | 1,509,000Source | 865,000Source | 1,277,000Source | 1,704,000Source | 984,000Source | 1,385,000Source | 1,747,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 694,000Source | 551,000Source | 2,686,000Source | 2,219,000Source | 1,765,000Source | 265,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -4,364,000Source | -5,275,000Source | -16,394,000Source | -11,901,000Source | -6,401,000Source | -4,066,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | -43,000Source | -262,000Source | -184,000Source | -495,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 43,000Source | 262,000Source | 184,000Source | 495,000Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 952,000Source | 0Source | 7,565,000Source | 16,907,000Source | 13,793,000Source | 5,925,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,412,000Source | -5,318,000Source | -9,091,000Source | 4,822,000Source | 6,897,000Source | 1,859,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 4,867,000Source | 7,827,000Source | 3,515,000Source | 8,845,000Source | 1,482,000Source | 8,667,000Source | 4,894,000Source | 13,985,000Source | 9,163,000Source | 2,266,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 4,000Source | 0Source | 204,000Source | 20,000Source | 2,000Source | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 704,000Source | 572,000Source | 707,000Source | 729,000Source | 694,000Source | 551,000Source | 2,686,000Source | 2,219,000Source | 1,765,000Source | 265,000Source |
| Debt Securities, Realized Gain (Loss)USD | — | — | 33,000Source | — | 0Source | 73,000Source | 54,000Source | -83,000Source | 352,000Source | -460,000Source | — | — |
| DepreciationUSD | — | — | 65,000Source | 38,000Source | 66,000Source | 60,000Source | 66,000Source | 53,000Source | 244,000Source | 157,000Source | 47,000Source | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | 849,000Source | — | — | — | — | 0Source | -417,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 2,249,000Source | 2,139,000Source | 2,375,000Source | 2,449,000Source | 2,115,000Source | 2,751,000Source | 9,242,000Source | 9,233,000Source | 6,521,000Source | 3,320,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 73,000Source | 79,000Source | 15,000Source | 50,000Source | 20,000Source | 99,000Source | 247,000Source | 251,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,778,000Source | -500,000Source | -4,117,000Source | -4,658,000Source | -5,000,000Source | -4,966,000Source | -18,646,000Source | -11,161,000Source | -16,485,000Source | -5,121,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -500,000Source | — | -4,658,000Source | — | -4,966,000Source | — | -11,161,000Source | -19,058,000Source | -5,121,000Source |
| Nonoperating Income (Expense)USD | — | — | -740,000Source | 2,852,000Source | -84,000Source | -168,000Source | 68,000Source | -435,000Source | -1,997,000Source | — | -213,000Source | — |
| Operating ExpensesUSD | — | — | 5,038,000Source | 3,352,000Source | 4,033,000Source | 4,490,000Source | 5,068,000Source | 4,531,000Source | 16,649,000Source | 13,737,000Source | 8,889,000Source | 4,467,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 2,000Source | -92,000Source | -625,000Source | -2,000Source | 0Source | -619,000Source | 32,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | 325,000Source | — | — | 706,000Source | 0Source | 6,590,000Source | 7,507,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -5,038,000Source | -3,352,000Source | -4,033,000Source | -4,490,000Source | -5,068,000Source | -4,531,000Source | -16,649,000Source | -13,737,000Source | -8,889,000Source | -4,467,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 2,000Source | -92,000Source | -625,000Source | -2,000Source | 0Source | -619,000Source | 32,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,778,000Source | -500,000Source | -4,117,000Source | -4,658,000Source | -5,000,000Source | -4,966,000Source | -18,646,000Source | -11,161,000Source | -16,485,000Source | -5,121,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.13Source | -0.01Source | -0.66Source | -2.41Source | -1.33Source | -2.71Source | -0.42Source | -0.34Source | -0.68Source | -0.18Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.13Source | -0.01Source | -0.66Source | -2.41Source | -1.33Source | -2.71Source | -0.42Source | -0.34Source | -0.68Source | -0.18Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 43,072,542Source | 33,516,656Source | 6,272,541Source | 1,931,763Source | 3,772,930Source | 1,833,656Source | 44,660,518Source | 32,875,075Source | 28,230,842Source | 28,230,842Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 43,072,542Source | 33,516,656Source | 6,272,541Source | 1,931,763Source | 3,772,930Source | 1,833,656Source | 44,660,518Source | 32,875,075Source | 28,230,842Source | 28,230,842Source |
| Additional Financial Items | ||||||||||||
| Debt Securities, Realized Gain (Loss)USD | — | — | 33,000Source | — | 0Source | 73,000Source | 54,000Source | -83,000Source | 352,000Source | -460,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 2,249,000Source | 2,139,000Source | 2,375,000Source | 2,449,000Source | 2,115,000Source | 2,751,000Source | 9,242,000Source | 9,233,000Source | 6,521,000Source | 3,320,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 147,000Source | 654,000Source |
| Interest Expense, DebtUSD | — | — | 0Source | 5,000Source | 7,000Source | 0Source | 4,000Source | 0Source | 204,000Source | 20,000Source | 65,000Source | 265,000Source |
| Investment Income, InterestUSD | — | — | 73,000Source | 79,000Source | 15,000Source | 50,000Source | 20,000Source | 99,000Source | 247,000Source | 251,000Source | — | — |
| Marketing and Advertising ExpenseUSD | — | — | 300,000Source | — | 100,000Source | 200,000Source | 200,000Source | 200,000Source | 700,000Source | 574,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -500,000Source | — | -4,658,000Source | — | -4,966,000Source | — | -11,161,000Source | -19,058,000Source | -5,121,000Source |
| Nonoperating Income (Expense)USD | — | — | -740,000Source | 2,852,000Source | -84,000Source | -168,000Source | 68,000Source | -435,000Source | -1,997,000Source | — | -213,000Source | — |
| Operating ExpensesUSD | — | — | 5,038,000Source | 3,352,000Source | 4,033,000Source | 4,490,000Source | 5,068,000Source | 4,531,000Source | 16,649,000Source | 13,737,000Source | 8,889,000Source | 4,467,000Source |
| Research and Development ExpenseUSD | — | — | 2,789,000Source | 1,213,000Source | 1,658,000Source | 2,041,000Source | 2,953,000Source | 1,780,000Source | 7,407,000Source | 4,504,000Source | 2,368,000Source | 1,147,000Source |
Offerings
Registration 333-280303
Registration 333-284077
Registration 333-297353
Registration 333-294713
- Gross proceeds
- 2999988.52
- Net proceeds
- 2789988.45
- Deal price
- 1.32
- Shares
- 2272719
- Offering price
- $1.32000
- Ticker
- FBLG
Underwriters: H.C. Wainwright & Co., LLC
Filing attachments
fblg-ex99_1.htm · 8-K · 2026-09-18
EX-99.1 2 fblg-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer HOUSTON, September 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today a…
Read attachment ↗fblg-ex4_1.htm · 8-K · 2026-09-15
EX-4.1 2 fblg-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO …
Read attachment ↗fblg-ex99_1.htm · 8-K · 2026-08-24
EX-99.1 2 fblg-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FibroBiologics Appoints Leigh Steinberg to Board of Directors Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins Board HOUSTON, August 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fi…
Read attachment ↗fblg-ex99_1.htm · 8-K · 2026-07-09
EX-99.1 2 fblg-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FibroBiologics Appoints Kathleen "Kate" Rubins, Ph. D. to Board of Directors Microbiologist, Retired NASA Astronaut, and Founding Director of the University of Pittsburgh Trivedi Institute for Space and Global Biomedicine Joins Board HOUSTON, July 9, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development o…
Read attachment ↗fblg-ex4_1.htm · 8-K · 2026-06-29
EX-4.1 2 fblg-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO …
Read attachment ↗fblg-ex4_2.htm · 8-K · 2026-06-29
EX-4.2 3 fblg-ex4_2.htm EX-4.2 EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO …
Read attachment ↗